KyungDong Pharm home
Prescription Medicines

Aepen Tab.

Product Category
muscle relaxant
Active Ingredients
Eperisone hydrochloride
Appearance
A white, round, film-coated tablet.
Reimbursement Code
648101570
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
- Active ingredient: Eperisone hydrochloride (KP) ----- 50mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, citric acid, Opagloss Clear (297W19196), Opadry White (03B28796), colloidal silicon oxide, povidone, hypromellose

2. Effectiveness
1. Painful muscle spasms accompanying musculoskeletal diseases: glenohumeral syndrome, periarthritis of the shoulder, back pain
2. Spastic paralysis due to nervous system disease: cerebrovascular disorder, spastic spinal paralysis, cervical spondylosis, postoperative sequelae (including brain and spinal cord tumors), traumatic sequelae (spinal cord injury, head trauma), amyotrophic axial sclerosis, cerebral palsy, spinocerebellar degeneration, spinal vascular disorder, subacute spinal optic nerve lesion, and other cerebrospinal cord diseases.

3. Dosage and dosage
Adults: Administer orally as eperisone hydrochloride, 50 mg once, three times a day, after meals.
Increase or decrease appropriately depending on age and symptoms.

4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to this drug
2) Patients with severe myasthenia gravis
3) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with a history of drug hypersensitivity
2) Patients with hepatic impairment (can worsen liver function)

3. Adverse reactions
1) Shock: In rare cases, shock may occur, so observe thoroughly and if symptoms appear, stop administration and take appropriate measures.
2) Liver: Rarely, an increase in ALT, AST, or ALP may occur. Therefore, if an abnormality is detected after sufficient observation, take appropriate measures such as discontinuing administration.
3) Kidney: In rare cases, proteinuria and an increase in BUN may occur. Therefore, sufficient observation should be conducted and if abnormalities are recognized, appropriate measures such as discontinuation of administration should be taken.
4) Blood: In rare cases, anemia may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration, if symptoms appear.
5) Hypersensitivity: Occasionally rash and rarely itching may occur.
6) Mental nervous system: Sometimes insomnia, drowsiness, headache, paralysis of the limbs, and in rare cases, stiffness of the body and tremors of the limbs may occur.
7) Digestive system: Occasionally nausea, vomiting, loss of appetite, stomach discomfort, dry mouth, constipation, diarrhea, abdominal pain, and rarely abdominal distension and stomatitis may occur.
8) Urinary system: In rare cases, urinary retention, urinary incontinence, and residual urine sensation may occur.
9) Systemic symptoms: Sometimes helplessness, staggering, general malaise, and rarely dizziness and decreased muscle tone may occur.
10) Others: Sometimes facial flushing, rarely sweating, and swelling may occur.
11) As a result of the analysis and evaluation of serious adverse events collected after domestic marketing, the confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Immune system: Anaphylactic reaction
12) As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-December 2018), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Skin and subcutaneous tissue - angioedema
13) Toxic epidermal necrolysis and mucous membrane-skin-eye syndrome (Stevens-Johnson syndrome): Eperisone hydrochloride can cause serious skin abnormalities such as toxic epidermal necrolysis and ocular mucocutaneous syndrome. Therefore, patients should be carefully observed for symptoms such as fever, erythema, blisters, itching, redness of the eyes, and stomatitis. If these symptoms appear, discontinue administration and take appropriate measures.

4. General precautions
1) While taking this drug, lethargy, grogginess, drowsiness, etc. may occur. In such cases, reduce the dose or stop taking the drug.
2) Because drowsiness and a decrease in attention, concentration, reflexes, etc. may occur, patients taking this drug should be careful not to operate dangerous machinery, such as driving a car.

5. Interaction
There have been reports of visual acuity disorders when used together with tolperisone hydrochloride, a similar drug, and methocarbamol.

6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) It is advisable to avoid administration to nursing mothers, but if administration is unavoidable, discontinue breastfeeding.

7. Administration to children
Safety for children has not been established (there is little experience with use).

8. Administration to elderly people
In general, elderly people have reduced physiological function, so be careful about reducing the amount.

9. Pharmaceutical equivalence test information Note 1
A. The test drug Daewoo Eperisone Tablet (eperisone hydrochloride) (Daewoo Pharmaceutical Co., Ltd.) and the control drug Murex tablet (eperisone hydrochloride) (Chodang Pharmaceutical Co., Ltd.) were administered to healthy adults in a single dose orally on an empty stomach in a 2x2 crossover test. As a result, blood eperisone was measured in 67 people. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, The 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.

Note 1. This drug was manufactured by Daewoo Pharmaceutical Co., Ltd. using the same raw materials as Daewoo Eperisone Tablet (eperisone hydrochloride) and the entire process was manufactured by Daewoo Pharmaceutical Co., Ltd. using the same manufacturing method.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 1000 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Aepen Tab.Precautions for use2021.09.22PDFChange comparison table.pdf
1Aepen Tab.Epen Tablet (Precautions for use)2018.03.30PDF0036_200009708_Precautions for use (Epen tablet).pdf